Prenatal Chromosomal Screening: NIPT, Serum Screening, CVS & Amniocentesis

Chromosomal screening assesses risk of aneuploidy (trisomy 21/18/13, sex chromosome differences). Options range from non-invasive screening to diagnostic testing.

Screening Tests (Risk Assessment, Not Diagnostic)

Diagnostic Tests (Definitive Karyotype)

  • CVS (10–13 wks): Transcervical/transabdominal chorionic villi sampling. Miscarriage risk ~0.2–0.5%. Detects all chromosomal anomalies; cannot detect neural tube defects (AFP needed).
  • Amniocentesis (≥15 wks): Amniotic fluid culture. Miscarriage risk ~0.1–0.3%. Detects chromosomal + NTDs (AFP).

Decision Framework

  1. Counseling: values, risk tolerance, desire for diagnostic certainty.
  2. Screening first (NIPT preferred for performance).
  3. If screen positive → diagnostic confirmation (CVS/amnio) before irrevocable decisions.
  4. If screen negative → reassurance; diagnostic still optional.

Emerging

  • Genome-wide NIPT (microdeletions, CNVs) — higher false positive, counseling complexity.
  • Non-invasive fetal karyotyping (whole genome) — research phase.

All testing is voluntary. Shared decision-making essential.

Pregnancy & Health - Related Articles

Health Sciences © https://www.222health.com

TestTimingComponentsDetection (T21)False Positive
NIPT (cfDNA)≥10 wksMaternal blood → fetal placental DNA>99%<0.1%
First Trimester Combined11–13+6 wksPAPP-A, β-hCG + NT ultrasound85–90%5%
Second Trimester Quad15–22 wksAFP, hCG, estriol, inhibin-A81%5–7%
Integrated/SequentialCombined 1st + 2ndBoth serum + NT90–95%2–5%